-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

Benzinga·03/11/2025 10:27:55
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $7 price target.